Welcome to our dedicated page for Shattuck Labs news (Ticker: $STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shattuck Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shattuck Labs's position in the market.
Shattuck Labs, Inc. (STTK) reported financial results for Q1 2024, highlighting progress in clinical trials for cancer treatments. They completed enrollment in Phase 1B cohorts for TP53m AML patients, presented preclinical data at AACR, and entered a collaboration with Ono Pharma. Financially, they have $114.6 million in cash and continue to focus on R&D.
